DYVOX Stock Analysis: Dynavox | ST
Medical Instruments & Supplies | ST, Sweden | Market Cap: 7.610m SEK | 12M Return: -12.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.3M
EPS Trend: 93.0%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Dynavox Group AB, formerly Tobii Dynavox, is a Stockholm-based medical technology company specializing in Augmentative and Alternative Communication (AAC) solutions. The company develops integrated hardware and software systems designed for individuals with speech and motor impairments resulting from conditions such as ALS, autism, and cerebral palsy.
The business model relies on a multi-disciplinary approach that includes product development, clinical training, and navigating complex insurance reimbursement frameworks. In the assistive technology sector, revenue is frequently driven by government-funded healthcare programs and educational grants, which provide the primary financing for high-cost speech-generating devices.
The company maintains a global footprint with operations across North America, Europe, and Asia-Pacific. By controlling the full ecosystem of AAC-including specialized eye-tracking hardware and proprietary language software-the firm creates high switching costs and high barriers to entry within the niche medical supplies industry.
- U.S. Medicare and insurance reimbursement policy changes impact AAC adoption
- High gross margins sustained by proprietary software and hardware integration
- Strategic acquisitions expand market share in specialized assistive technology segments
- Organic revenue growth driven by increased clinical awareness of AAC solutions
| Net Income: 226.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 7.91 > 1.0 |
| NWC/Revenue: 16.96% < 20% (prev 14.20%; Δ 2.76% < -1%) |
| CFO/TA 0.15 > 3% & CFO 405.6m > Net Income 226.0m |
| Net Debt (1.09b) to EBITDA (503.0m): 2.17 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (106.6m) vs 12m ago 0.28% < -2% |
| Gross Margin: 68.95% > 18% (prev 68.49%; Δ 0.46% > 0.5%) |
| Asset Turnover: 103.4% > 50% (prev 98.30%; Δ 5.10% > 0%) |
| Interest Coverage Ratio: 7.78 > 6 (EBIT TTM 323.0m / Interest Expense TTM 41.5m) |
| A: 0.16 (Total Current Assets 1.16b - Total Current Liabilities 728.0m) / Total Assets 2.62b |
| B: 0.27 (Retained Earnings 719.0m / Total Assets 2.62b) |
| C: 0.13 (EBIT TTM 323.0m / Avg Total Assets 2.46b) |
| D: 0.37 (Book Value of Equity 714.0m / Total Liabilities 1.91b) |
| Altman-Z'' = 3.25 = A |
| DSRI: 1.03 (Receivables 567.0m/488.0m, Revenue 2.54b/2.25b) |
| GMI: 0.99 (GM 68.49% / 68.95%) |
| AQI: 0.98 (AQ_t 0.45 / AQ_t-1 0.46) |
| SGI: 1.13 (Revenue 2.54b / 2.25b) |
| TATA: -0.07 (NI 226.0m - CFO 405.6m) / TA 2.62b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of July 28, 2026, the stock is trading at SEK 72.40 with a total of 449,261 shares traded. Over the past week, the price has changed by +10.62%, over one month by +18.79%, over three months by -15.36% and over the past year by -12.93%.
Current recommended Stop Loss: 64.00 (which is 11.6% or 2.1 ATR below the current price).
Dynavox has no consensus analysts rating.
P/E Trailing = 33.8443
P/S = 3.0761
P/B = 11.3493
Revenue TTM = 2.54b SEK
EBIT TTM = 323.0m SEK
EBITDA TTM = 503.0m SEK
Long Term Debt = 830.0m SEK (from longTermDebt, last quarter)
Short Term Debt = 111.0m SEK (from shortTermDebt, last quarter)
Debt = 1.31b SEK (from shortLongTermDebtTotal, last quarter) + Leases 208.0m
Net Debt = 1.09b SEK (calculated: Debt 1.31b - CCE 223.0m)
Enterprise Value = 8.70b SEK (7.61b + Debt 1.31b - CCE 223.0m)
Interest Coverage Ratio = 7.78 (Ebit TTM 323.0m / Interest Expense TTM 41.5m)
EV/FCF = 35.47x (Enterprise Value 8.70b / FCF TTM 245.3m)
FCF Yield = 2.82% (FCF TTM 245.3m / Enterprise Value 8.70b)
FCF Margin = 9.65% (FCF TTM 245.3m / Revenue TTM 2.54b)
Net Margin = 8.89% (Net Income TTM 226.0m / Revenue TTM 2.54b)
Gross Margin = 68.95% ((Revenue TTM 2.54b - Cost of Revenue TTM 789.0m) / Revenue TTM)
Gross Margin QoQ = 70.15% (prev 67.18%)
Tobins Q-Ratio = 3.32 (Enterprise Value 8.70b / Total Assets 2.62b)
Interest Expense / Debt = 3.16% (Interest Expense 41.5m / Debt 1.31b)
Taxrate = 20.49% (58.0m / 283.0m)
NOPAT = 256.8m (EBIT 323.0m * (1 - 20.49%))
Current Ratio = 1.59 (Total Current Assets 1.16b / Total Current Liabilities 728.0m)
Debt / Equity = 1.84 (Debt 1.31b / totalStockholderEquity, last quarter 714.0m)
Debt / EBITDA = 2.17 (Net Debt 1.09b / EBITDA 503.0m)
Debt / FCF = 4.44 (Net Debt 1.09b / FCF TTM 245.3m)
Total Stockholder Equity = 628.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.20% (Net Income 226.0m / Total Assets 2.62b)
RoE = 35.94% (Net Income TTM 226.0m / Total Stockholder Equity 628.9m)
RoCE = 22.14% (EBIT 323.0m / Capital Employed (Equity 628.9m + L.T.Debt 830.0m))
RoIC = 13.67% (NOPAT 256.8m / Invested Capital 1.88b)
WACC = 9.22% (E(7.61b)/V(8.92b) * Re(10.38%) + D(1.31b)/V(8.92b) * Rd(3.16%) * (1-Tc(0.20)))
Discount Rate = 10.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.00 | Cagr: 0.04%
[DCF] Terminal Value 75.20% ; FCFF base≈160.4m ; Y1≈183.8m ; Y5≈270.6m
[DCF] Fair Price = 23.00 (EV 3.53b - Net Debt 1.09b = Equity 2.44b / Shares 106.1m; r=9.22% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 93.03 | EPS CAGR: 33.51% | SUE: 0.36 | # QB: 0
Revenue Correlation: 99.04 | Revenue CAGR: 22.05% | SUE: 0.08 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.70 | Chg30d=-12.50% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=2.95 | Chg30d=-1.07% | Revisions=-17% | GrowthEPS=+89.1% | GrowthRev=+13.1%
EPS next Year (2027-12-31): EPS=4.02 | Chg30d=-0.94% | Revisions=-50% | GrowthEPS=+36.2% | GrowthRev=+18.6%
[Analyst] Revisions Ratio: -50% (up=1, down=6)